JAZZ — Jazz Pharmaceuticals Share Price
Last trade - 00:00- $6.73bn
- $9.85bn
- $4.07bn
- 88
- 83
- 92
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.8 | ||
| PEG Ratio (f) | 0.11 | ||
| EPS Growth (f) | 72.24% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.64 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 4.99 | ||
| Price to Sales | 1.65 | ||
| EV to EBITDA | 7.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.53% | ||
| Return on Equity | 14.31% | ||
| Operating Margin | 17.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,363.57 | 3,094.24 | 3,659.37 | 3,834.2 | 4,068.95 | 4,292.4 | 4,441.66 | 13.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +19.44 | n/a | n/a | -1.14 | +24.05 | +164.91 | -2.84 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Directors
- Bruce Cozadd CHM (57)
- Daniel Swisher PRE (58)
- Renee Gala CFO (49)
- Christopher Tovey COO (56)
- Kimberly Sablich EVP (52)
- Robert Iannone EVP (54)
- Finbar Larkin SVP (63)
- Neena Patil SVP (46)
- Samantha Pearce SVP (55)
- Patricia Carr CAO (50)
- Rick Winningham LED (61)
- Jennifer Cook IND (55)
- Patrick Enright IND (59)
- Peter Gray IND (66)
- Heather Mcsharry IND (59)
- Seamus Mulligan IND (60)
- Kenneth O'Keefe IND (54)
- Anne O'Riordan IND (53)
- Norbert Riedel IND (63)
- Mark Smith IND (69)
- Catherine Sohn IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 15th, 2005
- Public Since
- January 18th, 2012
- No. of Shareholders
- 882
- No. of Employees
- 2,800
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 60,732,479
- Address
- Fifth Floor, DUBLIN, 4
- Web
- https://www.jazzpharma.com/
- Phone
- +353 16347800
- Contact
- Andrea Flynn
- Auditors
- KPMG
Latest News for JAZZ
Upcoming Events for JAZZ
Q1 2025 Jazz Pharmaceuticals PLC Earnings Release
Q1 2025 Jazz Pharmaceuticals PLC Earnings Call
Jazz Pharmaceuticals PLC to Review Zepzelca Data at ASCO Annual Meeting
Jazz Pharmaceuticals PLC Annual Shareholders Meeting
Q2 2025 Jazz Pharmaceuticals PLC Earnings Release
Similar to JAZZ
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 03:25 UTC, shares in Jazz Pharmaceuticals are trading at $110.80. This share price information is delayed by 15 minutes.
Shares in Jazz Pharmaceuticals last closed at $110.80 and the price had moved by +3.14% over the past 365 days. In terms of relative price strength the Jazz Pharmaceuticals share price has underperformed the S&P500 Index by -4.8% over the past year.
The overall consensus recommendation for Jazz Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreJazz Pharmaceuticals does not currently pay a dividend.
Jazz Pharmaceuticals does not currently pay a dividend.
Jazz Pharmaceuticals does not currently pay a dividend.
To buy shares in Jazz Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $110.80, shares in Jazz Pharmaceuticals had a market capitalisation of $6.73bn.
Here are the trading details for Jazz Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: JAZZ
Based on an overall assessment of its quality, value and momentum Jazz Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Jazz Pharmaceuticals is $188.93. That is 70.51% above the last closing price of $110.80.
Analysts covering Jazz Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $23.31 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jazz Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +6.6%.
As of the last closing price of $110.80, shares in Jazz Pharmaceuticals were trading -6.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Jazz Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 4.8. The shares last closed at $110.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Jazz Pharmaceuticals' management team is headed by:
- Bruce Cozadd - CHM
- Daniel Swisher - PRE
- Renee Gala - CFO
- Christopher Tovey - COO
- Kimberly Sablich - EVP
- Robert Iannone - EVP
- Finbar Larkin - SVP
- Neena Patil - SVP
- Samantha Pearce - SVP
- Patricia Carr - CAO
- Rick Winningham - LED
- Jennifer Cook - IND
- Patrick Enright - IND
- Peter Gray - IND
- Heather Mcsharry - IND
- Seamus Mulligan - IND
- Kenneth O'Keefe - IND
- Anne O'Riordan - IND
- Norbert Riedel - IND
- Mark Smith - IND
- Catherine Sohn - IND